CervoMed Reports $6.6 Million Net Loss in Q2 2026, Completes $20.5 Million Financing

CervoMed Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $6.6 million, a slight increase from the $6.3 million loss recorded in the same period last year. For the first half of 2026, the company experienced a net loss of $14.5 million, compared to a loss of $11.2 million in the first half of 2025. The increase in losses was primarily attributed to a significant decline in grant revenue, which fell to zero in the current quarter from $1.8 million in the prior year, following the completion of the RewinD-LB Trial. Total operating expenses for the second quarter decreased by 20% to $6.7 million, down from $8.4 million in the previous year, driven by reductions in both research and development and general administrative costs.

CervoMed's research and development expenses for the second quarter were $4.3 million, a decrease of 15% from $5.1 million in the same quarter of 2025. This reduction was largely due to lower costs associated with the recently completed RewinD-LB Trial. General and administrative expenses also saw a significant decline, dropping 28% to $2.4 million from $3.3 million year-over-year, reflecting a decrease in personnel costs and professional fees. The company reported interest income of $0.1 million for the quarter, down from $0.4 million in the prior year, primarily due to a lower investment balance.

In terms of strategic developments, CervoMed completed two significant financing transactions in June 2026, raising approximately $20.5 million through a private placement and a registered direct offering. The private placement involved the sale of 3,360,377 units at $3.14 per unit, while the registered direct offering sold 2,500,000 shares at $4.00 each. These funds are intended to support ongoing research and development activities, particularly the advancement of neflamapimod into Phase 3 clinical trials for dementia with Lewy bodies (DLB). The company is also focusing on establishing strategic partnerships to facilitate this transition.

As of June 30, 2026, CervoMed reported cash, cash equivalents, and marketable securities totaling approximately $24.9 million, a significant increase from $8.2 million at the end of 2025. The company anticipates that its current financial resources will be sufficient to fund operations through the third quarter of 2027. However, CervoMed acknowledges the need for additional capital to continue its clinical development efforts and to potentially acquire or in-license new product candidates. The company has not yet generated revenue from product sales and does not expect to do so in the near future, emphasizing the importance of securing further funding to sustain its operations and growth initiatives.